Deep Expertise Across Functional Areas
Bringing together industry experts, blue-chip investors, and a cross-disciplinary team of top scientists in antibody drug discovery and disease biology, we’re translating therapeutics into the clinic. Meet our Management Team:
Phil is the Chief Executive Officer of Northern Biologics, and a member of the Northern Biologics Board of Directors. Prior to joining Northern Biologics, Phil served as Global Head of Research and Development and a member of the Executive Committee of Shire, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. Under Phil’s leadership Shire’s pipeline had approximately 40 programs in clinical development in the areas of Genetic Disease, GI disease, Hematology, Immunology, Neuroscience, Ophthalmology and Oncology. Prior to Shire, Phil held positions of increasing responsibility in Research and Development at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx Pharmaceuticals. Phil is also a member of the Board of Directors of Revance Therapeutics.
Phil obtained his PhD in Biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Jeanne Magram is the founding Chief Scientific Officer of Northern Biologics.
Prior to joining Northern Biologics, Jeanne served as the Site Head for Pfizer’s Centers for Therapeutic Innovation (CTI), New York, a model partnership between Pfizer and academic medical centers designed to accelerate the translation of innovative discoveries into differentiated new medicines to treat diseases of pressing unmet medical need. Prior to CTI, Jeanne was Vice President, Immunology & Inflammation Research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease. In this role, she delivered several candidates into clinical testing. Jeanne was also an Associate Director of GPCR Drug Discovery at OSI Pharmaceuticals after OSI’s acquisition of Cadus Pharmaceutical’s Drug Discovery programs, and spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Jeanne completed her postdoctoral training in the laboratory of Nobel Laureate Dr. J. Michael Bishop at the University of California, San Francisco and obtained her PhD in the laboratory of Dr. Frank Costantini in Genetics and Development at Columbia University.
Dr. Wasserman is the Chief Medical Officer at Northern Biologics as of December, 2016. Dr. Wasserman’s expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development. From May 2014 through November 2016, Dr. Wasserman was responsible for leading the medical strategy for Oncology and Malignant Hematology as the Global Therapeutic Area Head for Covance, the CRO division of LabCorp. He was the leader for the physician group that monitors global and regional Oncology trials for clients. He led the cross-business unit team responsible for educating employees and promoting their Immuno-Oncology expertise and capabilities as part of a corporate strategic initiative.
Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. Prior to his employment at Roche, he was the Deputy Director of the Oncology Biomarker group aat Novartis after starting his pharmaceutical career at Merck. Dr. Wasserman earned his M.D. from Johns Hopkins University School of Medicine, and completed his Pediatric Residency and Pediatric Hematology-Oncology fellowship training at The Children’s Hospital of Philadelphia, University of Pennsylvania. After completing his training, he stayed on as an Assistant Professor for nine years.
Rahul joined as Chief Business Officer of Northern Biologics in May 2016. Prior to Northern, Rahul was VP of Business Development at Flexion Therapeutics (FLXN) where he led the company through several key transactions, including a $150MM strategic manufacturing partnership with Patheon UK. Prior to Flexion, he ran business development at the Broad Institute where he completed several out-licensing deals, including the one that founded Verastem (VSTM). Rahul started his career in Silicon Valley as the founder/CEO of Redmind, a venture backed data analytics startup that he sold to Ikimbo Inc., in 2002.
Rahul has a PhD in cancer biology from Georgetown School of Medicine, an MS in bioinformatics from Johns Hopkins, and a BA from Brown University. He also completed his Kauffman Fellowship (Class 15) at Novartis Venture Funds.
Judit joined Northern Biologics as VP of Operations and Corporate Affairs in June 2017. Previously, Judit was co-founder of Mosaic Biomedicals, a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action targeting cancer stem cells and the tumor’s immune system. As Mosaic’s CEO, Judit led the growth of the company until its merger with Northern in 2016. Prior to Mosaic, Judit was Associate at the Pipeline and Portfolio Planning team collaborating with the Oncology & Hemathology Franchise at Genentech Inc. (CA, US).
Judit holds a Master in Business Administration (MBA) from Duke University (NC, US) with a certification in Health Sector Management and concentration in Entrepreneurship and Innovation. In addition, she received her PhD from the University of Barcelona (Spain) and has 10+ years of scientific career in translational oncology at the Vall d’Hebron Institute of Oncology (Spain). Judit is recipient of merit-based scholarships from the Spanish Association Against Cancer (AECC), Rafael del Pino Foundation, Caja Madrid Foundation and Duke University’s Julian Connally Scholarship.